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Abstract
Trial participants from limited resource settings often are 
given very little or nothing in terms of  compensation for time, 
inconvenience and risks as compared to their counterparts 
from developed countries.  The reason that is often sited 
by researchers, ethics committees, and sponsors is the 
avoidance of  undue inducements.  We discuss the inherent 
conflict that may arise in trying to avoid undue inducement 
and in trying to minimize injustice in international research. 
We argue that research participants from both industrialized 
nations and those from limited resource settings should be 
compensated equally since they suffer the same burdens 
and equally contribute towards the study by contributing 
the same product – data.   We make recommendations 
that acknowledge and address the existing injustice in the 
compensation of  trial participants in international research. 
Introduction
A significant amount of  literature exists on the subject of  
compensating trial participants for participating in research, 
1-5 however very little has been written specifically on the 
compensation of  participants within international research, 
especially research that is sponsored by industrialized 
countries and is conducted in developing countries or is 
conducted in both developed and developing countries. 
Presently there is an increase in the amount of  research being 
conducted in developing countries which is mostly sponsored 
by developed countries. Fears continue to be expressed in 
developing countries on the possibility of  exploitation of  
individuals and communities who may be used as inexpensive 
sources of  data in clinical trials since they are  cheaper to 
compensate as compared to trial participants from developed 
countries.  This paper focuses on the issues of  fairness in 
compensating research participants in international research 
from the point of  view of  developing countries. We propose 
justice in decision making on compensation of  research 
participants in both the developed and developing countries 
since trial participants from both settings share “equally” in 
both the burdens and benefits of  research.   Data from a 
participant in a developing country is as useful as data from 
a research participant from a developed country.  Data from 
both developed and developing countries is collated in order 
to come up with conclusive findings.  This therefore implies 
that equal weight should be given to all the trial participants 
within a study whether or not they are from a limited resource 
settings or from a developed countries. 
The issue of  compensating trial participants can be viewed 
from two levels; the micro level which focuses on the research 
participant who directly participates in the research, and the 
macro level which focuses on communities or countries that 
participate in research and also includes the global situation 
. At the micro level, there is need to consider that both 
participants from both industrialized countries and limited 
resource settings are contributing equally towards the same 
study.  They suffer the same burdens and hence they need 
to be compensated equally.  Both participants from the two 
settings have to be paid for inconvenience, time spent, pain 
and have to receive reimbursements for other study related 
expenses.     
Compensation: a definition
We define compensation in research as “something done 
to make up for losses or costs incurred in the course of  
participating in a study”.  Compensation covers payments 
for participation (time) as well as reimbursements for costs 
associated with participation in a clinical trial. 6 Payments 
to research participants for participation in studies are not 
considered as benefits.  Compensation is not always straight 
forward to calculate. Compensation that is easy to address 
includes reimbursements for meals, babysitting, and bus 
fare to and from the research site. Reimbursements involve 
refunding the trial participants for any resources they 
would have used or that they are expected to use in order 
to participate in a trial.e.g. transport and lunch.   There are 
three categories of  compensation payments that are often 
problematic and are difficult to calculate.  These are payments 
for time, pain and inconvenience.  Some trials require visits 
that last much longer than a normal visit to the health centre. 
In those circumstances, one may receive compensation for 
his time.   Some studies require multiple blood draws, X-
rays, pap smears and other uncomfortable procedures such 
that one has to be compensated for the discomforts if  one 
consents to such procedures.   Clinical trial participants may 
also receive compensation for taking on the risks of  receiving 
an experimental medication, especially if  it may not directly 
benefit them.7   Individuals may also be compensated for 
their blood sample, tissues, or body fluids.
Models for Compensating Research Participants 
Payments for time, inconvenience and risk are difficult to 
calculate because so many factors are involved which are 
both personal and economic.  There are four basic models 
for compensating participants for trial participation: the 
market model, the wage payment model, the fair share 
model and the reimbursement model.  With the market 
model, the laws of  supply and demand determine how 
much a trial participant should be paid, whilst with the wage 
payment model compensation is based on the premise that 
the research participation is an unskilled labourer and the 
research participants are paid on the scale commensurate 
with that of  an unskilled labourer.  With the fair share model, 
research participants are compensated a fixed amount that 
is determined to be fair.  With the reimbursement model, 
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payment is only permitted to cover the participants’ expenses 
such as food, travel and lost wages. The market model, the 
wage payment model and the fair share model, accommodate 
the use of  payments to induce people to participate in 
research whilst the reimbursement model strictly deals with 
the costs to the participant associated with participation.8,9 
The reimbursement model also does not have room to 
accommodate compensation for inconvenience, risk and 
pain.
Calculating compensation
In international research, calculating compensation levels 
becomes a very complex exercise that investigators, sponsors 
and ethics committees would rather not tackle.  Compensating 
trial participants for time, pain and inconvenience is difficult 
to calculate since it is based on the value of  an individual’s time 
and the cost they attach to the pain and inconvenience.   The 
value of  an individual’s time depends on several factors such 
as local economic conditions and individual personalities. 
What may be one person’s due inducement may be another 
person’s undue inducement.  Whilst it is acknowledged that 
compensation for time, pain and inconvenience are difficult 
to calculate, it is generally agreed that trial participants 
need to be compensated for their time, pain, risks and 
other inconveniences.  Compensating participants for their 
participation and serves as a means of  appreciating the 
risks and inconveniences of  participating in research since 
participation in research, represents some form of  sacrifice.  
During a workshop for investigators from various African 
Countries, the majority of  investigators reported that in 
most internationally funded clinical trials being conducted 
in their countries, research participants amount an amount 
ranging between $3 and  $5 as compensation for all costs 
associated with participation .9  The reason that is often given 
by investigators, sponsors and ethics committees for this is 
to avoid undue inducement for participants from limited 
resource settings.  A $100 compensation may be regarded as 
appropriate and non-coercive in a developed country setting 
and yet it represents several months’ earnings for someone 
working in a developing country.   This illustration presents 
a realistic conflict between avoiding undue inducement in 
limited resource settings and in developed countries. 
Situations do exist where individuals participate in risky 
studies if  high amounts of  money are offered particularly 
if  the large sums of  money can solve financial problems. 
This situations do also developed countries where the term 
“professional research subject” has been coined to describe 
people who depend on participating in clinical trials for 
survival.  Such persons benefit from the cash that is offered 
as compensation for participation.  College students and 
the homeless are well known to be a very good source of  
research participants in developed country settings because 
of  their urgent need for cash.10 - 14
In a study conducted among clinical trial participants in Kenya, 
respondents indicated that monetary compensation for time, 
inconvenience and risks was necessary and they indicated 
that they could use the cash to buy other life sustaining 
requirements such as antiretroviral drugs.  Some participants 
even indicated that since they had no other sources of  income, 
the cash could prevent them from engaging in risky activities 
such as prostitution.  Some participants even suggested that 
researchers can compensate them using other means such 
as hard goods, foodstuffs or donations to local institutions 
and supporting organizations.  Other respondents viewed 
their participation in terms of  assisting the researchers to 
do their work.  They therefore thought that it was only fair 
for participants to be compensated for participating in the 
researchers’ studies.   In the same study, some leading to 
risky behaviours such as consumption of  alcohol .15   Such 
fears reflect a conflict between the need to be fair to the trial 
participant and the need to avoid harm to the participant. 
This study highlights that research, besides providing new 
evidence, can also play the additional role of  improving 
people’s standard of  living.  
Sponsors and investigators need to realize that future access 
to individuals and communities lies with the preceding 
research conducted using those individuals and within those 
communities.   Researchers need to realize that the amount of  
time that is spent by participants could be spent doing other 
beneficial things such as tending domestic animals, weeding 
crops or gathering fire wood.  Most participants willing to 
be involved in clinical trials are women who have additional 
responsibilities such as taking care of  children, gardens, and 
household duties
Several investigators from various African countries 
also reported that some participants  are now  aware of  
the disparity  that exists in compensating them for their 
participation.  The investigators further reported that some 
people are now refusing to participate in studies which do 
not compensate them for their participation are becoming 
common and participants are beginning to request for 
higher amounts for compensation.9 Locally sponsored 
research usually does not offer levels of  compensation 
that are equal to those offered by internationally sponsored 
research due to the limited resources set aside for health 
research.  This has led to deterioration in the quality of  
locally sponsored research as a result of  the unwillingness 
of  individuals to participate in such studies in favour of  the 
better paying internationally funded trials.  It is also possible 
that once participants become aware that they are being paid 
inappropriately less in comparison to their counterparts in 
industrialized nations, they may develop this same attitude 
even towards internationally sponsored trials.   
Recommendations
In trying to strike a balance between the need to avoid 
undue inducement and the need to avoid injustice in the 
way trial participants from limited resource settings and 
those from developed countries are compensated, we 
suggest that compensation can be in different forms such 
as food, hard goods and even health care.  Compensation 
in the form of  health care can include comprehensive 
follow-up and provision of  treatment.   This may even be 
extended to the period after the trial.  Compensation may 
also be provided through providing care for other non-
study illnesses discovered during the clinical trials.    Such 
care needs to be extended to communities where possible, 
so that high quality care offered through trial sites, may not 
be viewed as an undue inducement.  This proposal will also 
assist sponsors and investigators in avoiding the difficulties 
surrounding the issue of  dealing with cash in compensating 
trial participants.  The issue of  provision of  ancillary care 
continues to be debated and there is a significant amount of  
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literature covering the debates.16-20
Some researchers have been quick to point out that their role 
is not to improve standards of  living for participants, but they 
need to realize that without those people who volunteer, there 
would be no clinical trials.  Some researchers have suggested 
that the improvement of  people’s living conditions is the 
duty of  donor agencies and not research sponsoring agencies. 
They have therefore suggested exchange programmes and 
consultations as a way forward.21  We propose too that in 
the interest of  protecting locally funded research, some 
of  the benefits as well as compensatory payments from 
internationally sponsored research may be converted into 
community benefits such as supporting clinics, electrifying 
community centres and schools, installation of  boreholes 
or piped water, or engaging in other community projects 
which promote good health.    We would even go as far 
as encouraging countries to come up with ways of  raising 
resources from international research grants that can then be 
used to support local research as well as research institutions. 
Funds from research grants may also be used in technology 
transfer and in training and adequately remunerating 
personnel from resource limited settings   This may reduce 
the current brain drain in favour of  the developed countries 
and may also reduce the exportation of  specimens to 
developed countries “for further analysis”, whilst ultimately 
improving the capacity of  developing countries to conduct 
research that directly addresses their own needs.  
Another mechanism of  ensuring that locally funded 
research trials do not suffer at the hands of  internationally 
funded research, is to set levels of  compensation and 
incentives that need to be adhered to for both locally and 
internationally funded trials.  A certain percentage of  the 
budget for internationally funded trials can then be diverted 
to other health promotion activities or programmes for 
the communities participating in the trials.  In response to 
this proposal, some researchers have been quick to point 
out that it is not proper to use research funds for health 
promoting activities that are not related to the study being 
conducted.  However, research is supposed to contribute 
towards improvements in health and this can be achieved in 
various ways.  Other researchers have expressed fears that 
implementing such alternatives would be very complex and 
would require a substantial investment at the beginning.22 
We argue that a major investment is necessary to change the 
mind-set of  researchers and sponsors –so they realize there 
is injustice in the compensation of  trial participants from 
limited resource settings.  
The involvement of  communities from limited resource 
settings in research as well as the offer of  community 
benefits, should not serve as a way of  shifting bias from 
patient level decision making towards institutional or 
community decision making.  This simply is the addition of  
an additional layer of  protection for vulnerable individuals. 
At the end of  the day, studies do not deal with communities 
but with specific individuals within the community who 
have to make individual decisions.  Community decisions 
such as community refusals can be made at community level 
through the communities, their leaders and also through 
the ethics committees.   Refusals by communities assist in 
protecting vulnerable individuals within those communities. 
If  the results from the study will not be applicable to the 
community nor the individuals taking part in the study, then 
no level of  community compensation can be justifiable.   
In our opinion, health research should play a part in 
redressing the current global imbalances by participating 
in the global processes of  re-distribution of  resources. 
Channelling of  resources to developing countries for 
various initiatives including community development 
efforts, will avoid exposing individual participants to undue 
inducement.  Community benefits can contribute to all the 
individuals within that community.  The research and ethics 
committees (RECs) in developing countries can play an 
important role by addressing the issue of  compensation and 
advising investigators appropriately.  We suggest that RECs 
should negotiate on behalf  of  their communities for fair 
compensation. RECs should ensure that before granting 
permission for any study, they have critically looked at the 
population the participants will be drawn from, the amount 
of  compensation being offered, and the capacity building 
efforts proposed at institutional, community and or national 
level.  .
Conclusion
Individual, community and national compensation for 
participation in any research is ethical and that compensation 
should not only be in monetary terms but can also take 
other forms such as food and treatment follow-up.  At 
the national level, compensation may come in the form of  
technology transfer, scientific, technical and medical training, 
installation and ongoing maintenance of  infrastructure such 
as laboratories, clinics, libraries and other facilities. We also 
argue that research ethics committees should negotiate 
compensation and community benefits for their communities. 
Ethics committees in limited resource settings need to go 
beyond the question of  whether payments constitute an 
undue inducement.  They should consider whether the 
payment is fair considering the risks, inconveniences and 
pain that the research participants has to undertake absorb, 
and also consider the time the participant could have spent 
performing other duties.
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